RxDoctor Payments Data

Jerry Kennett, MD

Cardiovascular Disease · Columbia, MONPI 1851383145

Payments from drug & device makers

$1,201in general payments, 2019–2025

Across 61 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$168
  • Amgen$132
  • Novartis$113
  • Kiniksa Pharmaceuticals International, PLC$96
  • Johnson & Johnson$77
  • Novo Nordisk$74
  • plus $539 from 13 others

What the payments were for

  • Food & beverage$1,18799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,201 in reported general payments places this provider in the 40th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$318,670
Medicare patients
1,136
Services billed
5,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban754$679,119
EntrestoSacubitril/Valsartan325$270,090
XareltoRivaroxaban216$214,183
Repatha SureclickEvolocumab215$192,110
FarxigaDapagliflozin Propanediol123$93,610
JardianceEmpagliflozin57$56,063
Praluent PenAlirocumab29$25,773
OzempicSemaglutide22$20,243
JanuviaSitagliptin Phosphate16$12,540
Metoprolol Succinate847$12,116
MounjaroTirzepatide11$11,718
TrulicityDulaglutide12$11,538
SotalolSotalol Hcl483$9,956
Atorvastatin Calcium906$8,372
Torsemide413$7,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$679,119754 claims
NovartisEntresto$113$270,090325 claims
Johnson & JohnsonXarelto$77$214,183216 claims
AstraZenecaFarxiga$33$93,610123 claims
Boehringer IngelheimJardiance$42$56,06357 claims
Novo NordiskOzempic$74$20,24322 claims
MerckJanuvia$62$12,54016 claims
Sanofi-aventis U.S. LLCLantus$51$3,79127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →